KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guerin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)

被引：2

作者：

Shariat, S. F. ^{[1
]}

Steinberg, G. ^{[2
]}

Kamat, A. M. ^{[3
]}

Shore, N. D. ^{[4
]}

Alanee, S. ^{[5
,6
]}

Nishiyama, H. ^{[7
]}

Nam, K. ^{[8
]}

Godwin, J. L. ^{[8
]}

Kapadia, E. ^{[8
]}

Hahn, N. ^{[9
]}

机构：

[1] Med Univ Vienna, Urol, Vienna, Austria

[2] NYU Langone Hlth, Urol, New York, NY USA

[3] Univ Texas MD Anderson Canc Ctr, Urol, Houston, TX 77030 USA

[4] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA

[5] Michigan State Univ, Urol, Detroit, MI USA

[6] Michigan State Univ, Detroit Med Ctr, Detroit, MI USA

[7] Univ Tsukuba, Urol, Tsukuba, Ibaraki, Japan

[8] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[9] Johns Hopkins Univ, Sch Med, Med Oncol, Baltimore, MD USA

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.114

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

718TiP

引用

页码：S723 / S723

页数：1

共 50 条

[1] Randomized comparator-controlled study evaluating efficacy and safety of pembrolizumab plus Bacillus Calmette-Guerin (BCG) in patients with high-risk nonmuscle-invasive bladder cancer (HR NMIBC): KEYNOTE-676 cohort B.
Kamat, Ashish M.
Shariat, Shahrokh
Steinberg, Gary D.
Alanee, Shaheen Riadh
Nishiyama, Hiroyuki
Nam, Kijoeng
Kapadia, Ekta
Shore, Neal D.
Hahn, Noah M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[2] Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction.
Kamat, Ashish M.
Shore, Neal D.
Hahn, Noah M.
Alanee, Shaheen
Nishiyama, Hiroyuki
Shariat, Shahrokh
Nam, Kijoeng
Kapadia, Ekta
Frenkl, Tara L.
Steinberg, Gary D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[3] Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.
Kamat, Ashish M.
Shore, Neal D.
Hahn, Noah M.
Alanee, Shaheen Riadh
Nishiyama, Hiroyuki
Shariat, Shahrokh F.
Nam, Kijoeng
Kapadia, Ekta
Frenkl, Tara L.
Steinberg, Gary D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[4] Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial
de Wit, R.
Kulkarni, G. S.
Uchio, E.
Singer, E. A.
Krieger, L.
Grivas, P.
Bajorin, D.
Seo, H. K.
Mourey, L.
Kamat, A.
Nishiyama, H.
Kapadia, E.
Nam, K.
Frenkl, T.
Balar, A.
[J]. ANNALS OF ONCOLOGY, 2018, 29 : 304 - 304
[5] Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guerin (BCG)-unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC)
Gupta, S.
Kulkarni, G.
Necchi, A.
Shore, N. D.
Dave, H.
Kapadia, E.
Zhao, Q.
Kamat, A.
[J]. EUROPEAN UROLOGY, 2024, 85 : S433 - S433
[6] Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG).
Balar, Arjun Vasant
Kulkarni, Girish S.
Uchio, Edward M.
Boormans, Joost
Mourey, Loic
Krieger, Laurence Eliot Miles
Singer, Eric A.
Bajorin, Dean F.
Kamat, Ashish M.
Grivas, Petros
Seo, Ho Kyung
Nishiyama, Hiroyuki
Konety, Badrinath R.
Nam, Kijoeng
Kapadia, Ekta
Frenkl, Tara L.
De Wit, Ronald
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[7] Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
Shore, Neal D.
Nishiyama, Hiroyuki
Shariat, Shahrokh F.
Steinberg, Gary
Kamat, Ashish M.
Alanee, Shaheen Riadh
Nam, Kijoeng
Imai, Kentaro
Kapadia, Ekta
Hahn, Noah M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS722 - TPS722
[8] PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG): EFFICACY AND EVALUATION OF SUBSEQUENT CYSTECTOMY FROM COHORT B OF THE PHASE 2 KEYNOTE-057 STUDY
Singer, Eric
Necchi, Andrea
Roumiguie, Mathieu
Esen, Ahmet Adil
Lebret, Thierry
de Wit, Ronald
Bajorin, Dean F.
Krieger, Laurence E. M.
Kandori, Shuya
Uchio, Edward M.
Seo, Ho Kyung
Boormans, Joost
Kamat, Ashish M.
Grivas, Petros
Nishiyama, Hiroyuki
Baranwal, Pranshu
Kapadia, Ekta
Van den Sigtenhorst-Fijlstra, Margot
Kulkarni, Girish S.
Shore, Neal D.
[J]. JOURNAL OF UROLOGY, 2023, 209 : E1195 - E1195
[9] Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C
Necchi, A.
Shore, N. D.
Gupta, S.
Kulkarni, G.
Dave, H.
Kapadia, E.
Zhao, Q.
Kamat, A.
[J]. EUROPEAN UROLOGY, 2023, 83 : S748 - S748
[10] Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG): Updated follow-up from KEYNOTE-057.
De Wit, Ronald
Kulkarni, Girish S.
Uchio, Edward M.
Krieger, Laurence Eliot Miles
Boormans, Joost L.
Roumiguie, Mathieu
Singer, Eric A.
Bajorin, Dean F.
Kamat, Ashish M.
Grivas, Petros
Seo, Ho Kyung
Nishiyama, Hiroyuki
Konety, Badrinath R.
Nam, Kijoeng
Kapadia, Ekta
Frenkl, Tara L.
Balar, Arjun Vasant
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →